Form 4: Celldex Therapeutics Director, Garry A. Neil, Reports Stock Option Grant
SEC Form 4 Filing
Director Garry A. Neil reports acquisition of 16,500 non-qualified stock options in Celldex Therapeutics.
Summary
- Garry A. Neil, a director of Celldex Therapeutics, Inc., filed a Form 4 on June 17, 2024, reporting a transaction.
- On June 13, 2024, Neil acquired 16,500 non-qualified stock options with an exercise price of $36.43.
- These options, granted under the company's 2021 Omnibus Equity Incentive Plan, are exercisable starting June 13, 2025, and expire on June 13, 2034.
- Following the transaction, Neil directly owns 16,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a routine stock option grant. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, common in the biotechnology industry as part of executive compensation packages.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of stock option grant |
| 06/13/2025 | Options become exercisable |
| 06/13/2034 | Options expiration date |
| 06/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.